Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05426681 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Spinal Cord Injury Neuroprotection With Glyburide

Study acronym: SCING
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: University of Kentucky to Francis Farhadi
    • Site contact updated
    v8
  2. 3 versions Re-verified since Oct 3, 2023, no change to tracked fieldsv5-v7
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 2022 to Jul 7, 2022
    v4
  4. Start date: Sep 2022 to Nov 2022v3
  5. Start date: Jun 2022 to Sep 2022v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.
Trial Details
NCT Number NCT05426681
Lead Sponsor Francis Farhadi
Conditions
(from sponsor)		 Acute Spinal Cord Injury
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov